MX2017002275A - Derivado de azaindol que tiene actividad activadora de proteina cinasa activada por monofosfato de adenosina (ampk). - Google Patents

Derivado de azaindol que tiene actividad activadora de proteina cinasa activada por monofosfato de adenosina (ampk).

Info

Publication number
MX2017002275A
MX2017002275A MX2017002275A MX2017002275A MX2017002275A MX 2017002275 A MX2017002275 A MX 2017002275A MX 2017002275 A MX2017002275 A MX 2017002275A MX 2017002275 A MX2017002275 A MX 2017002275A MX 2017002275 A MX2017002275 A MX 2017002275A
Authority
MX
Mexico
Prior art keywords
group
substituted
unsubstituted
halogen atom
alkenyl
Prior art date
Application number
MX2017002275A
Other languages
English (en)
Inventor
Tamura Yuusuke
Kojima Eiichi
Hinata Yu
Ozasa Hiroki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX2017002275A publication Critical patent/MX2017002275A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Se proporciona un compuesto que es útil como activador de AMPK. Un compuesto representado por la fórmula: (ver Fórmula) o su sal farmacéuticamente aceptable, en donde X es alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido o heterociclilo sustituido o no sustituido; R1 es hidrógeno, halógeno, ciano, nitro, carboxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, acilo sustituido o no sustituido, carbamoilo sustituido o no sustituido, alquiltio sustituido o no sustituido, alquilsulfinilo sustituido o no sustituido, alquilsulfonilo sustituido o no sustituido o alquiloxicarbonilo sustituido o no sustituido; R2 es halógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, arilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, o similares; R3 es halógeno, hidroxi, ciano, nitro, carboxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, o similares; y R4 es hidrógeno, halógeno, hidroxi, ciano, nitro, carboxi, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, o similares.
MX2017002275A 2014-08-27 2015-08-26 Derivado de azaindol que tiene actividad activadora de proteina cinasa activada por monofosfato de adenosina (ampk). MX2017002275A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2014172192 2014-08-27
JP2015009894 2015-01-22
JP2015072597 2015-03-31
PCT/JP2015/073947 WO2016031842A1 (ja) 2014-08-27 2015-08-26 Ａｍｐｋ活性化作用を有するアザインドール誘導体

Publications (1)

Publication Number Publication Date
MX2017002275A true MX2017002275A (es) 2017-05-03

Family

ID=55399728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002275A MX2017002275A (es) 2014-08-27 2015-08-26 Derivado de azaindol que tiene actividad activadora de proteina cinasa activada por monofosfato de adenosina (ampk).

Country Status (10)

Country Link
US (1) US9980948B2 (es)
EP (1) EP3187498A4 (es)
JP (1) JP6579550B2 (es)
KR (1) KR20170044184A (es)
CN (1) CN107108605A (es)
AU (1) AU2015309863B2 (es)
CA (1) CA2959293A1 (es)
MX (1) MX2017002275A (es)
RU (1) RU2017107543A (es)
WO (1) WO2016031842A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2700703C2 (ru) 2014-10-28 2019-09-19 Сионоги Энд Ко., Лтд. Гетероциклическое производное, обладающее активирующей ampk активностью
CN109071536A (zh) * 2016-02-26 2018-12-21 盐野义制药株式会社 具有ampk活化作用的5-苯基氮杂吲哚衍生物
CN109311912A (zh) * 2016-04-26 2019-02-05 盐野义制药株式会社 具有ampk活化作用的5-取代氮杂苯并咪唑衍生物
EP3459949A4 (en) * 2016-05-20 2020-04-08 Shionogi & Co., Ltd 5-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE WITH AMPK ACTIVATION EFFECT
CN113402502B (zh) * 2019-05-16 2022-10-14 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体制备的物料组合体系
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009212462B2 (en) 2008-02-04 2012-09-13 Mercury Therapeutics, Inc. AMPK modulators
CA2737694C (en) 2008-09-26 2013-07-02 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2741300A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
GB0915892D0 (en) 2009-09-10 2009-10-14 Smithkline Beecham Corp Compounds
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
RU2635662C2 (ru) 2010-09-10 2017-11-15 Сионоги Энд Ко., Лтд. Конденсированное с гетерокольцом имидазольное производное, обладающее активирующим амрк действием
MA34916B1 (fr) 2011-02-25 2014-02-01 Merck Sharp & Dohme Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
JP6108467B2 (ja) 2011-07-15 2017-04-05 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するアザベンズイミダゾール誘導体
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2014031441A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydrofuran derivatives
EP2888008B1 (en) 2012-08-22 2018-12-26 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydrofuran derivatives
RU2015109706A (ru) 2012-08-22 2016-10-10 Мерк Шарп И Доум Корп. Новые производные азабензимидазол гексагидрофуро[3, 2-в]фурана
WO2014031468A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole hexahydrofuro[3,2-b]furan derivatives
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives
WO2014031445A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel benzimidazole tetrahydropyran derivatives
WO2014069426A1 (ja) * 2012-10-31 2014-05-08 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体
EP2769974A1 (en) 2013-02-21 2014-08-27 Debiopharm S.A. Novel AMPK activator
EP2963013A4 (en) 2013-02-27 2016-09-14 Shionogi & Co INDOLE AND AZAINDOLE DERIVATIVES HAVING AMPK ACTIVATION ACTIVITY EACH
US9650375B2 (en) * 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
AU2014292236B2 (en) 2013-07-17 2018-11-08 Boehringer Ingelheim International Gmbh New azabenzimidazole derivatives
EP3063148B1 (en) 2013-10-31 2020-04-29 Boehringer Ingelheim International GmbH Azabenzimidazole derivatives
WO2016001224A1 (en) 2014-06-30 2016-01-07 Debiopharm International S.A. Novel activators of amp-activated protein kinases
JP6588966B2 (ja) 2014-08-11 2019-10-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｍｐタンパク質キナーゼ作動薬としてのアザベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
CA2959293A1 (en) 2016-03-03
US9980948B2 (en) 2018-05-29
RU2017107543A3 (es) 2019-02-25
EP3187498A4 (en) 2018-01-17
RU2017107543A (ru) 2018-10-02
JPWO2016031842A1 (ja) 2017-06-22
AU2015309863A1 (en) 2017-03-16
EP3187498A1 (en) 2017-07-05
US20170273955A1 (en) 2017-09-28
AU2015309863B2 (en) 2019-12-05
AU2015309863A8 (en) 2017-04-06
KR20170044184A (ko) 2017-04-24
WO2016031842A1 (ja) 2016-03-03
JP6579550B2 (ja) 2019-09-25
CN107108605A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
MX2017002275A (es) Derivado de azaindol que tiene actividad activadora de proteina cinasa activada por monofosfato de adenosina (ampk).
PH12016501813B1 (en) 1,3-benzodioxole derivative
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
TW201613911A (en) Heterocyclic compounds and uses thereof
WO2016011390A8 (en) Irak4 inhibiting agents
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
MX2016011992A (es) Derivados de piperidina-diona.
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
MX2015010837A (es) Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas.
MY194116A (en) Pharmaceutical compounds
MX2015011913A (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
MX368178B (es) Compuestos de ácido dimetilbenzoico.
MX2015017156A (es) Inhibidores de bace.
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
AU2015211852A1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
MY176921A (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MX2017016030A (es) Derivado de dihidropirrolopirazol sustituido.
MX2015011375A (es) Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1].
JOP20200030A1 (ar) مركب خماسي الحلقة
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative
WO2015102024A3 (en) Novel substituted 5 membered heterocyclic compounds and preparation thereof